New Treatment For Hepatitis
A new oral
antiviral treatment for hepatitis B - adefovir dipivoxil.
of adefovir dipivoxil offers a new weapon in the treatment of
chronic hepatitis B.
dipivoxil has been clinically proven
be effective even in patients who develop resistance
existing oral medication.
availability of adefovir dipivoxil as another treatment option
for chronic hepatitis B will give doctors a new level of
manage this disease
patients, it signifies new hope.
dipivoxil works by suppressing the replication of the hepatitis
B virus (HBV) in patients taking a single daily 10 mg tablet. It
was approved the US Food and Drug Administration based on data
from two randomized. Double-blind, placebo-controlled trials.
These studies found that patients receiving adefovir dipivoxil
showed significant improvement in liver inflammation caused by
the HBV. The trials also
demonstrated the effectiveness of the antiviral drug in treating
patients with clinical symptom of HBV who had not responded
approved antiviral therapies.
is a serious and highly infectious disease that attacks the
liver. Complications of hepatitis B include cirrhosis (hardening
of the liver), liver failure and primary liver cancer. The
majority of patients are infected during childbirth from an
Transmission also occurs between partners through unprotected
sex. Hepatitis B vaccinations for new-born have been compulsory
since 1989 in an effort to curb the spread of the disease.
Worldwide, there are about 350 million chronic carriers of
hepatitis B; an estimated 75 percent of them are found in Asia
and Western Pacific regions.